Parabolic Drugs Ltd. announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported net sales (net of duties) of INR 162.8 million against INR 242.6 million a year ago. Loss before exceptional and extraordinary items and tax was INR 150.8 million against INR 446.8 million a year ago. Loss before extraordinary items and tax was INR 150.8 million against INR 446.8 million a year ago. Net loss after tax from continuing operations was INR 154.7 million against INR 454.5 million a year ago. Basic and diluted loss per share was INR 2.50 against INR 7.33 a year ago. For the nine months, the company reported net sales (net of duties) of INR 555.7 million against INR 492.4 million a year ago. Loss before exceptional and extraordinary items and tax was INR 410.2 million against INR 1,636.7 million a year ago. Loss before extraordinary items and tax was INR 410.2 million against INR 1,636.7 million a year ago. Net loss after tax from continuing operations was INR 423.1 million against INR 1,659.9 million a year ago. Basic and diluted loss per share was INR 6.84 against INR 26.79 a year ago.